Insulin secretion levels necessary for efficacy of an alpha-glucosidase inhibitor on glucose metabolism in patients with non-insulin-dependent diabetes mellitus.
Twenty patients with non-insulin-dependent diabetes mellitus whose glucose metabolism was unsatisfactory, even though they were receiving appropriate dietary therapy, were treated with an alpha-glucosidase inhibitor (0.6 mg/day) for 12 weeks. The connecting peptide immunoreactivity value (selected as the evaluation criterion of post-prandial endogenous insulin secretion) was compared in patients with and without improved glycosylated haemoglobin levels. A significant difference was found between the connecting peptide immunoreactivity value of the group with improved glycosylated haemoglobin levels (5.0 +/- 1.0 ng/ml) and that in the group without the improvement (2.7 +/- 0.9 ng/ml).
Okada
S
S
Third Department of Internal Medicine, Okayama University Medical School, Japan.
Ishii
K
K
Hamada
H
H
Tanokuchi
S
S
Ichiki
K
K
Ota
Z
Z
D001786:Blood Glucose / Q000187:drug effects / Q000378:metabolism*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology*; D003927:Diet, Diabetic; D004435:Eating; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006442:Glycated Hemoglobin / Q000378:metabolism; D065089:Glycoside Hydrolase Inhibitors; D006801:Humans; D007294:Inositol / Q000031:analogs & derivatives* / Q000627:therapeutic use; D007328:Insulin / Q000097:blood / Q000378:metabolism*; D000078790:Insulin Secretion; D008297:Male; D008875:Middle Aged; D013997:Time Factors
D001786:Blood Glucose; D004791:Enzyme Inhibitors; D006442:Glycated Hemoglobin; D065089:Glycoside Hydrolase Inhibitors; D007294:Inositol; D007328:Insulin; C102817:voglibose